ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE capsule, extended release

United States - English - NLM (National Library of Medicine)

Buy It Now

Active ingredient:
ASPIRIN (UNII: R16CO5Y76E) (ASPIRIN - UNII:R16CO5Y76E), DIPYRIDAMOLE (UNII: 64ALC7F90C) (DIPYRIDAMOLE - UNII:64ALC7F90C)
Available from:
Golden State Medical Supply
Administration route:
ORAL
Prescription type:
PRESCRIPTION DRUG
Therapeutic indications:
Aspirin and Extended-Release Dipyridamole Capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Aspirin and Extended-Release Dipyridamole Capsules are contraindicated in patients with known hypersensitivity to any of the product components. Aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (NSAID) products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. Aspirin may cause severe urticaria, angioedema or bronchospasm. Do not use aspirin in children or teenagers with viral infections because of the risk of Reye syndrome. Risk Summary Available data from published studies and postmarketing experience with Aspirin and Extended-Release Dipyridamole Capsules use during pregnancy have not identified a clear association between Aspirin and Extended-Release Dipyridamole Capsules use and major birth defects, miscarriage, or adverse maternal or feta
Product summary:
Aspirin and Extended-Release Dipyridamole Capsules are available as a No. 00 capsule with Pink Opaque cap and Yellow Opaque body imprinted in black with “ Lannett ” and “330”, and filled with pellets and powder blend. Aspirin and Extended-Release Dipyridamole Capsules are supplied in unit-of-use bottles of 60 capsules (NDC 51407-271-60). Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Protect from excessive moisture.
Authorization status:
Abbreviated New Drug Application
Authorization number:
51407-271-60

ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE- aspirin and extended-release

dipyridamole capsule, extended release

Golden State Medical Supply

----------

HIGHLIGHTS OF PRESCRIBING INFORMATION

ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE CAPSULES.

These highlights do not include all the information needed to use ASPIRIN AND EXTENDED-RELEASE

DIPYRIDAMOLE CAPSULES safely and effectively. See full prescribing information for ASPIRIN AND

EXTENDED-RELEASE DIPYRIDAMOLE CAPSULES.

ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE capsules, for oral use

Initial U.S. Approval: 1999

RECENT MAJOR CHANGES

Warnings and Precautions, Stress testing with intravenous dipyridamole and other adenosinergic agents (

5.6) 12/2019

INDICATIONS AND USAGE

Aspirin and Extended-Release Dipyridamole Capsules are a combination antiplatelet agent indicated to reduce the risk

of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis ( 1)

DOSAGE AND ADMINISTRATION

One capsule twice daily (morning and evening) with or without food ( 2)

In case of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the

morning; resume BID dosing within one week ( 2.1)

Do not chew capsule ( 2)

Not interchangeable with the individual components of aspirin and dipyridamole tablets ( 2)

Dispense in this unit-of-use container ( 16)

DOSAGE FORMS AND STRENGTHS

Capsule: 25 mg aspirin/200 mg extended-release dipyridamole ( 3)

CONTRAINDICATIONS

Hypersensitivity to any product ingredients ( 4.1)

Patients with known allergy to NSAIDs ( 4.2)

Patients with the syndrome of asthma, rhinitis, and nasal polyps ( 4.2)

WARNINGS AND PRECAUTIONS

Aspirin and Extended-Release Dipyridamole Capsules increases the risk of bleeding ( 5.1)

Avoid use in patients with severe hepatic or renal insufficiency ( 5.2, 5.3)

Interrupt Aspirin and Extended-Release Dipyridamole Capsules 24-48 hours before using intravenous dipyridamole or

other adenosinergic agents for stress testing ( 5.6, 7.1)

ADVERSE REACTIONS

The most frequently reported adverse reactions (>10% and greater than placebo) were headache, dyspepsia,

abdominal pain, nausea, and diarrhea ( 6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Lannett Company, Inc. at 1-844-834-0530 or FDA at 1-

800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Co-administration with anticoagulants, antiplatelets, or NSAIDs can increase risk of bleeding ( 7.1)

Decreased renal function can occur with co-administration with NSAIDs ( 7.1)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 1/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

RECENT MAJOR CHANGES

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Alternative Regimen in Case of Intolerable Headaches

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

4.1 Hypersensitivity

4.2 Allergy

4.3 Reye Syndrome

5 WARNINGS AND PRECAUTIONS

5.1 Risk of Bleeding

5.2 Renal Failure

5.3 Hepatic Insufficiency

5.4 Coronary Artery Disease

5.5 Hypotension

5.6 Stress Testing with Intravenous Dipyridamole and Other Adenosinergic Agents

5.7 General

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Post-Marketing Experience

7 DRUG INTERACTIONS

7.1 Drug Interaction Study Information Obtained From Literature

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Patients with Severe Hepatic or Severe Renal Dysfunction

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

FULL PRESCRIBING INFORMATION

Sections or subsections omitted from the full prescribing information are not listed.

1 INDICATIONS AND USAGE

Aspirin and Extended-Release Dipyridamole Capsules are indicated to reduce the risk of stroke in

patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

2 DOSAGE AND ADMINISTRATION

Aspirin and Extended-Release Dipyridamole Capsules are not interchangeable with the individual

components of aspirin and dipyridamole tablets.

The recommended dose of Aspirin and Extended-Release Dipyridamole Capsules is one capsule given

orally twice daily, one in the morning and one in the evening. Swallow capsules whole without

chewing. Aspirin and Extended-Release Dipyridamole Capsules can be administered with or without

food.

2.1 Alternative Regimen in Case of Intolerable Headaches

In the event of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-

dose aspirin in the morning. Because there are no outcome data with this regimen and headaches

become less of a problem as treatment continues, patients should return to the usual regimen as soon as

possible, usually within one week.

3 DOSAGE FORMS AND STRENGTHS

No. 00 capsule with Pink Opaque cap and Yellow Opaque body imprinted in black with “ Lannett” and

“330”, and filled with pellets and powder blend.

4 CONTRAINDICATIONS

4.1 Hypersensitivity

Aspirin and Extended-Release Dipyridamole Capsules are contraindicated in patients with known

hypersensitivity to any of the product components.

4.2 Allergy

Aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug

(NSAID) products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. Aspirin may

cause severe urticaria, angioedema or bronchospasm.

4.3 Reye Syndrome

Do not use aspirin in children or teenagers with viral infections because of the risk of Reye syndrome.

5 WARNINGS AND PRECAUTIONS

5.1 Risk of Bleeding

Aspirin and Extended-Release Dipyridamole Capsules increase the risk of bleeding. Risk factors for

bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants,

antiplatelet agents, heparin, anagrelide, fibrinolytic therapy, and chronic use of NSAIDs) [see Drug

Interactions ( 7.1)] .

Intracranial Hemorrhage

In European Stroke Prevention Study-2 (ESPS2), the annualized event rate for intracranial hemorrhage

was 0.39%/year in the Aspirin and Extended-Release Dipyridamole Capsules group, 0.26%/year in the

extended-release dipyridamole (ER-DP) group, 0.24%/year in the aspirin (ASA) group, and 0.29%/year

extended-release dipyridamole (ER-DP) group, 0.24%/year in the aspirin (ASA) group, and 0.29%/year

in the placebo groups.

Gastrointestinal (GI) Side Effects

GI side effects include stomach pain, heartburn, nausea, vomiting, and gross GI bleeding. Although

minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy,

physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI

symptoms. Inform patients about the signs and symptoms of GI side effects and what steps to take if they

occur.

In ESPS2, the annualized event rate for gastrointestinal bleeding was 2.97%/year in the Aspirin and

Extended-Release Dipyridamole Capsules group, 1.58%/year in the extended-release dipyridamole

group, 2.06%/year in the aspirin group, and 1.40%/year in the placebo groups.

Peptic Ulcer Disease

Avoid using aspirin in patients with a history of active peptic ulcer disease, which can cause gastric

mucosal irritation and bleeding.

Alcohol Warning

Because Aspirin and Extended-Release Dipyridamole Capsules contain aspirin, counsel patients who

consume three or more alcoholic drinks every day about the bleeding risks involved with chronic,

heavy alcohol use while taking aspirin.

5.2 Renal Failure

Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute)

[see Use in Specific Populations ( 8.6) and Clinical Pharmacology ( 12.3) ] .

5.3 Hepatic Insufficiency

Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole

administration [see Use in Specific Populations ( 8.6) and Clinical Pharmacology ( 12.3) ] .

5.4 Coronary Artery Disease

Dipyridamole has a vasodilatory effect. Chest pain may be precipitated or aggravated in patients with

underlying coronary artery disease who are receiving dipyridamole.

For stroke or TIA patients for whom aspirin is indicated to prevent recurrent myocardial infarction (MI)

or angina pectoris, the aspirin in this product may not provide adequate treatment for the cardiac

indications.

5.5 Hypotension

Dipyridamole produces peripheral vasodilation, which can exacerbate pre-existing hypotension.

5.6 Stress Testing with Intravenous Dipyridamole and Other Adenosinergic Agents

Clinical experience suggests that patients being treated with Aspirin and Extended-Release

Dipyridamole Capsules who also require pharmacological stress testing with intravenous dipyridamole

or other adenosinergic agents (e.g. adenosine, regadenoson) should interrupt Aspirin and Extended-

Release Dipyridamole Capsules for 24-48 hours prior to stress testing [see Drug Interactions ( 7.1)] .

Intake of Aspirin and Extended-Release Dipyridamole Capsules 24-48 hours prior to stress testing with

intravenous dipyridamole or other adrenosinergic agents may increase the risk for cardiovascular side

effects of these agents and impair the sensitivity of the test.

5.7 General

Aspirin and Extended-Release Dipyridamole Capsules are not interchangeable with the individual

components of aspirin and dipyridamole tablets.

6 ADVERSE REACTIONS

The following adverse reactions are discussed elsewhere in the labeling:

Hypersensitivity [see Contraindications ( 4.1)]

Allergy [see Contraindications ( 4.2)]

Risk of Bleeding [see Warnings and Precautions ( 5.1)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed

in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug

and may not reflect the rates observed in practice.

The efficacy and safety of Aspirin and Extended-Release Dipyridamole Capsules was established in the

European Stroke Prevention Study-2 (ESPS2). ESPS2 was a double-blind, placebo-controlled study that

evaluated 6602 patients over the age of 18 years who had a previous ischemic stroke or transient

ischemic attack within ninety days prior to entry. Patients were randomized to either Aspirin and

Extended-Release Dipyridamole Capsules, aspirin, ER-DP, or placebo [see Clinical Studies ( 14)] ;

primary endpoints included stroke (fatal or nonfatal) and death from all causes.

This 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the

efficacy and safety of Aspirin and Extended-Release Dipyridamole Capsules with placebo, extended-

release dipyridamole alone and aspirin alone. The study was conducted in a total of 6602 male and

female patients who had experienced a previous ischemic stroke or transient ischemia of the brain

within three months prior to randomization.

Table 1 presents the annualized event rate for adverse events that occurred in 1%/year or more of

patients treated with Aspirin and Extended-Release Dipyridamole Capsules where the incidence was

also at least 1%/year greater than in those patients treated with placebo. There is no clear benefit of the

dipyridamole/aspirin combination over aspirin with respect to safety.

Table 1 Incidence of Adverse Events in ESPS2a

Nausea

(11.53)

(11.18)

210 (8.32)

232 (9.53)

Diarrhea

(9.17)

(11.31)

112 (4.44)

161 (6.61)

Vomiting

(6.03)

(5.68)

101 (4.00) 118 (4.84)

Platelet, Bleeding and Clotting Disorders

Hemorrhage NOS

(2.27)

(1.06)

(1.82)

(0.99)

Reported by ≥1%/year of patients during Aspirin and Extended-Release Dipyridamole Capsules

Individual Treatment Group

Body

System/Preferred

Term

Aspirin and Extended-Release

Dipyridamole Capsules

n (%/year)

ER-DP Alone

n (%/year)

ASA Alone

n (%/year)

Placebo

n (%/year)

Total Number of

Patients

1650

1654

1649

1649

Central and Peripheral Nervous System Disorders

Headache

(28.25)

(27.91)

558 (22.10) 543 (22.29)

Gastrointestinal System Disorders

Dyspepsia

(13.23)

(12.68)

299 (11.84)275 (11.29)

Abdominal Pain

(12.62)

(11.22)

262 (10.38)239 (9.81)

Reported by ≥1%/year of patients during Aspirin and Extended-Release Dipyridamole Capsules

treatment where the incidence was at least 1%/year greater than in those treated with placebo.

Annual event rate per 100 pt-years = 100* number of subjects with event/subject-years. Subject-years

is defined as cumulative number of days on treatment divided by 365.25.

Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for

all treatment groups is BID.

NOS = not otherwise specified.

Discontinuation due to adverse events in ESPS2 was 25% for Aspirin and Extended-Release

Dipyridamole Capsules, 25% for extended-release dipyridamole, 19% for aspirin, and 21% for placebo

(refer to Table 2).

Table 2 Incidence of Adverse Events that Led to the Discontinuation of Treatmenta

Treatment Groups

Aspirin and Extended-

Release Dipyridamole

Caps ules

n (%/year)

ER-DP

n (%/year)

ASA

n (%/year)

Placebo

n (%/year)

Total Number of Patients

1650

1654

1649

1649

Patients with at least one Adverse

Event that led to treatment

discontinuation

(18.21)

(18.44)

(12.59)

(14.45)

Headache

(7.20)

166 (7.31)

57 (2.26)

69 (2.83)

Nausea

(3.97)

(4.18) 51 (2.02)

53 (2.18)

Abdominal Pain

(3.23)

(2.82)

56 (2.22)

52 (2.13)

Vomiting

(2.31)

(2.29)

28 (1.11)

24 (0.99)

Reported by ≥1%/year of patients during Aspirin and Extended-Release Dipyridamole Capsules

treatment where the incidence was at least 1%/year greater than in those treated with placebo.

Annual event rate per 100 pt-years = 100* number of subjects with event/subject-years. Subject-years

is defined as cumulative number of days on treatment divided by 365.25.

Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for

all treatment groups is BID.

Headache was most notable in the first month of treatment.

6.2 Post-Marketing Experience

The following is a list of additional adverse reactions that have been reported either in the literature or

are from post-marketing spontaneous reports for either dipyridamole or aspirin. Because these

reactions are reported voluntarily from a population of uncertain size, it is not always possible to

estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to

include these reactions in labeling are typically based on one or more of the following factors: (1)

seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to Aspirin

and Extended-Release Dipyridamole Capsules.

Body as a Whole: Hypothermia, chest pain, allergic reaction, syncope

Cardiovascular: Angina pectoris, hypotension

Central Nervous System: Cerebral edema, dizziness, cerebral hemorrhage, intracranial hemorrhage,

subarachnoid hemorrhage

Fluid and Electrolyte: Hyperkalemia, metabolic acidosis, respiratory alkalosis, hypokalemia

Gastrointestinal: Pancreatitis, Reye syndrome, hematemesis, gastritis, ulceration and perforation,

hemorrhage rectum, melena, GI hemorrhage

Hearing and Vestibular Disorders: Hearing loss

Heart Rate and Rhythm Disorders: Tachycardia, palpitation

Immune System Disorders: Hypersensitivity, acute anaphylaxis, laryngeal edema

Liver and Biliary System Disorders: Hepatitis, hepatic failure, cholelithiasis, jaundice, hepatic function

abnormal

Musculoskeletal: Rhabdomyolysis, myalgia

Metabolic and Nutritional Disorders: Hypoglycemia, dehydration

Platelet, Bleeding and Clotting Disorders: Prolongation of the prothrombin time, disseminated

intravascular coagulation,

coagulopathy, thrombocytopenia, hematoma, gingival bleeding, epistaxis, purpura

Psychiatric Disorders: Confusion, agitation

Respiratory: Tachypnea, dyspnea, hemoptysis

Skin and Appendages Disorders: Rash, alopecia, angioedema, Stevens-Johnson syndrome, skin

hemorrhages such as bruising,

ecchymosis, and hematoma, pruritus, uticaria

Urogenital: Interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure,

hematuria

Vascular (Extracardiac) Disorders: Allergic vasculitis, flushing

Other Adverse Events: Anorexia, aplastic anemia, migraine, pancytopenia, thrombocytosis.

7 DRUG INTERACTIONS

7.1 Drug Interaction Study Information Obtained From Literature

Adenosinergic agents (e.g. adenosine, regadenoson)

Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.

Adjustment of adenosine dosage may be necessary. Dipyridamole also increases the cardiovascular

effects of regadenoson, an adenosine A

-receptor agonist. The potential risk of cardiovascular side

effects with intravenous adenosinergic agents may be increased during the testing period when

dipyridamole is not held 48 hours prior to stress testing.

Angiotensin Converting Enzyme (ACE) Inhibitors

Because of the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic

and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin.

Acetazolamide

Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide

(and toxicity) due to competition at the renal tubule for secretion.

Anticoagulants and Antiplatelets

Patients taking Aspirin and Extended-Release Dipyridamole Capsules in combination with

anticoagulants, antiplatelets, or any substance impacting coagulation are at increased risk for bleeding.

Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the

prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin,

increasing bleeding risk.

Anagrelide

Anagrelide

Patients taking aspirin in combination with anagrelide are at an increased risk of bleeding.

Anticonvulsants

Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total

concentration of phenytoin and an increase in serum valproic acid levels.

Beta Blockers

The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin

due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid

retention.

Cholinesterase Inhibitors

Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby

potentially aggravating myasthenia gravis.

Diuretics

The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be

diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading

to decreased renal blood flow and salt and fluid retention.

Methotrexate

Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the

elderly or renal impaired.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

The concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal

function.

Oral Hypoglycemics

Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to

hypoglycemia.

Uricosuric Agents (probenecid and sulfinpyrazone)

Salicylates antagonize the uricosuric action of uricosuric agents.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available data from published studies and postmarketing experience with Aspirin and Extended-Release

Dipyridamole Capsules use during pregnancy have not identified a clear association between Aspirin

and Extended-Release Dipyridamole Capsules use and major birth defects, miscarriage, or adverse

maternal or fetal outcomes (see Data). Aspirin and Extended-Release Dipyridamole Capsules contain

low-dose aspirin which is an NSAID (see Clinical Considerations). In animal reproduction studies, there

were adverse developmental effects with administration of aspirin in rats and rabbits at doses about 66

and 44 times, respectively, the human exposure at the maximum recommended daily dose of aspirin-

dipyridamole. Reproduction studies with dipyridamole in mice, rabbits, and rats have revealed no

evidence of harm to the fetus up to doses about 25 times the maximum recommended daily human dose

of aspirin-dipyridamole. Nonclinical data are suggestive of a possible potentiation of aspirin-related

fetal toxicity when combined with dipyridamole (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population is

unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In

the U.S. general population, the estimated background risk of major birth defects and miscarriage in

clinically recognized pregnancies is 2-4 and 15-20%, respectively.

Clinical Considerations

Labor and Delivery

Aspirin and Extended-Release Dipyridamole Capsules, which contains dipyridamole and low-dose

aspirin, increases the risk for bleeding [see Warnings and Precautions ( 5.1)] . Maternal use of high-dose

aspirin can result in excessive blood loss at delivery, prolonged gestation, prolonged labor, intracranial

hemorrhage in premature infants, low birth weight, stillbirth, and neonatal death.

Data

Human Data

Published data from clinical trials, observational studies, case series, and case reports over several

decades have not identified a clear association between aspirin-dipyridamole use in pregnancy and

major birth defects, miscarriage, or adverse maternal or fetal outcomes. However, these studies cannot

definitively establish the absence of any aspirin-dipyridamole associated risks. Methodological

limitations of these studies include variability in the timing and dose of drug exposure (e.g., most

exposures occurred beyond the first trimester) and the small sample sizes of individual studies.

Animal Data

Aspirin has been shown to be teratogenic in rats (spina bifida, exencephaly, microphthalmia and

coelosomia) and rabbits (congested fetuses, agenesis of skull and upper jaw, generalized edema with

malformation of the head, and diaphanous skin) at oral doses of 330 mg/kg/day and 110 mg/kg/day,

respectively. These doses, which also resulted in a high resorption rate in rats (63% of implantations

versus 5% in controls), are, on a mg/m

basis, about 66 and 44 times, respectively, the dose of aspirin

contained in the maximum recommended daily human dose of aspirin-dipyridamole. Reproduction

studies with dipyridamole have been performed in mice, rabbits and rats at oral doses of up to 125

mg/kg, 40 mg/kg, and 1000 mg/kg, respectively (about 1½, 2, and 25 times the maximum recommended

daily human oral dose, respectively, on a mg/m

basis) and have revealed no evidence of harm to the

fetus due to dipyridamole. When 330 mg aspirin/kg/day was combined with 75 mg dipyridamole/kg/day

in the rat at doses about 66 and 2 times, respectively, the maximum recommended daily human dose, the

resorption rate approached 100%.

8.2 Lactation

Risk Summary

Based on data from a clinical lactation study in breastfeeding women taking low-dose aspirin, the

metabolite salicylic acid is present in human milk in low levels (see Data). Dipyridamole is also present

in human milk. There is no information on the effects of Aspirin and Extended-Release Dipyridamole

Capsules or dipyridamole on the breastfed infant or on milk production. There is insufficient

information to determine the effects of aspirin on the breastfed infant and no information on the effects

of aspirin on milk production. The developmental and health benefits of breastfeeding should be

considered along with the mother’s clinical need for Aspirin and Extended-Release Dipyridamole

Capsules and any potential adverse effects on the breastfed child from Aspirin and Extended-Release

Dipyridamole Capsules or from the underlying maternal condition.

Data

A published clinical study involved six exclusively breastfeeding women at 1 to 8 months postpartum

who were taking 81 mg aspirin daily. Milk samples were collected at steady state, at 0, 1, 2, 4, 8, 12, and

24 hours after taking a dose of aspirin. Aspirin was undetectable in human milk. Salicylic acid was

present in milk at low levels (average concentration of 24 ng/mL). Based on an average milk

consumption of 150 mL/kg/day, the calculated relative infant dose was 0.4%. No adverse effects on the

breastfed infants were noted.

8.4 Pediatric Use

Safety and effectiveness of Aspirin and Extended-Release Dipyridamole Capsules in pediatric patients

have not been studied. Because of the aspirin component, use of this product in the pediatric population

is not recommended [see Contraindications ( 4.3)] .

8.5 Geriatric Use

Of the total number of subjects in ESPS2, 61% were 65 and over, while 27% were 75 and over. No

overall differences in safety or effectiveness were observed between these subjects and younger

subjects, and other reported clinical experience has not identified differences in responses between the

elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see

Clinical Pharmacology ( 12.3)] .

8.6 Patients with Severe Hepatic or Severe Renal Dysfunction

Aspirin and Extended-Release Dipyridamole Capsules have not been studied in patients with hepatic or

renal impairment. Avoid using aspirin containing products, such as Aspirin and Extended-Release

Dipyridamole Capsules, in patients with severe hepatic or severe renal (glomerular filtration rate < 10

mL/min) dysfunction [see Warnings and Precautions ( 5.2, 5.3) and Clinical Pharmacology ( 12.3)] .

10 OVERDOSAGE

Because of the dose ratio of dipyridamole to aspirin, overdosage of Aspirin and Extended-Release

Dipyridamole Capsules is likely to be dominated by signs and symptoms of dipyridamole overdose. In

case of real or suspected overdose, seek medical attention or contact a Poison Control Center

immediately. Careful medical management is essential.

Based upon the known hemodynamic effects of dipyridamole, symptoms such as warm feeling, flushes,

sweating, restlessness, feeling of weakness, and dizziness may occur. A drop in blood pressure and

tachycardia might also be observed.

Salicylate toxicity may result from acute ingestion (overdose) or chronic intoxication. Severity of

aspirin intoxication is determined by measuring the blood salicylate level. The early signs of salicylic

overdose (salicylism), including tinnitus (ringing in the ears), occur at plasma concentrations

approaching 200 µg/mL. In severe cases, hyperthermia and hypovolemia are the major immediate threats

to life. Plasma concentrations of aspirin above 300 µg/mL are clearly toxic. Severe toxic effects are

associated with levels above 400 µg/mL. A single lethal dose of aspirin in adults is not known with

certainty but death may be expected at 30 g.

Treatment of overdose consists primarily of supporting vital functions, increasing drug elimination, and

correcting acid-base disturbances. Consider gastric emptying and/or lavage as soon as possible after

ingestion, even if the patient has vomited spontaneously. After lavage and/or emesis, administration of

activated charcoal as a slurry may be beneficial if less than 3 hours have passed since ingestion.

Charcoal absorption should not be employed prior to emesis and lavage. Follow acid-base status

closely with serial blood gas and serum pH measurements. Maintain fluid and electrolyte balance.

Administer replacement fluid intravenously and augment with correction of acidosis. Treatment may

require the use of a vasopressor. Infusion of glucose may be required to control hypoglycemia.

Administration of xanthine derivatives (e.g., aminophylline) may reverse the vasodilatory effects of

dipyridamole overdose. Plasma electrolytes and pH should be monitored serially to promote alkaline

diuresis of salicylate if renal function is normal. In patients with renal insufficiency or in cases of life-

threatening intoxication, dialysis is usually required to treat salicylic overdose; however, since

dipyridamole is highly protein bound, dialysis is not likely to remove dipyridamole. Exchange

transfusion may be indicated in infants and young children.

11 DESCRIPTION

Aspirin and Extended-Release Dipyridamole Capsules are a combination antiplatelet agent intended for

oral administration. Each hard gelatin capsule contains 200 mg dipyridamole in an extended-release

pellet form and 25 mg aspirin in an immediate-release powder form. In addition, each capsule contains

the following inactive ingredients: hydrogenated castor oil, hypromellose 2910, hypromellose

phthalate, methacrylic acid copolymer, microcrystalline cellulose, povidone, simethicone emulsion,

starch, talc, tartaric acid and triacetin. The imprinting ink also contains ammonium hydroxide, n-butyl

alcohol, black iron oxide, isopropyl alcohol, propylene glycol and shellac glaze.

Each capsule shell contains gelatin, red iron oxide and yellow iron oxide and titanium dioxide.

Dipyridamole

Dipyridamole is an antiplatelet agent chemically described as 2,2',2'',2'''-[(4,8-

Dipiperidinopyrimido[5,4- d]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. It has the following structural

formula:

Dipyridamole is an odorless yellow crystalline substance, having a bitter taste. It is soluble in dilute

acids, methanol and chloroform, and is practically insoluble in water.

Aspirin

The antiplatelet agent aspirin (acetylsalicylic acid) is chemically known as benzoic acid, 2- (acetyloxy)-,

and has the following structural formula:

Aspirin is an odorless white needle-like crystalline or powdery substance. When exposed to moisture,

aspirin hydrolyzes into salicylic and acetic acids, and gives off a vinegary odor. It is highly lipid

soluble and slightly soluble in water.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The antithrombotic action of Aspirin and Extended-Release Dipyridamole Capsules is the result of the

additive antiplatelet effects of dipyridamole and aspirin.

Dipyridamole

Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro

and in vivo; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5–1.9

µg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the

platelet A

-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'-

adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in

response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate

(ADP).

Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE

is weak, therapeutic levels of dipyridamole inhibit cyclic-3',5'-guanosine monophosphate-PDE (cGMP-

PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing

factor, now identified as nitric oxide).

Aspirin

Aspirin inhibits platelet aggregation by irreversible inhibition of platelet cyclooxygenase and thus

inhibits the generation of thromboxane A

, a powerful inducer of platelet aggregation and

vasoconstriction.

12.2 Pharmacodynamics

The effect of either agent on the other's inhibition of platelet reactivity has not been evaluated.

12.3 Pharmacokinetics

There are no significant interactions between aspirin and dipyridamole. The kinetics of the components

are unchanged by their co-administration as Aspirin and Extended-Release Dipyridamole Capsules.

Absorption

Dipyridamole:

Peak plasma levels of dipyridamole are achieved 2 hours (range 1–6 hours) after administration of a

daily dose of 400 mg Aspirin and Extended-Release Dipyridamole Capsules (given as 200 mg BID).

The peak plasma concentration at steady-state is 1.98 μg/mL (1.01–3.99 μg/mL) and the steady-state

trough concentration is 0.53 μg/mL (0.18–1.01 μg/mL).

Aspirin:

Peak plasma levels of aspirin are achieved 0.63 hours (0.5–1 hour) after administration of a 50 mg

aspirin daily dose from Aspirin and Extended-Release Dipyridamole Capsules (given as 25 mg BID).

The peak plasma concentration at steady-state is 319 ng/mL (175-463 ng/mL). Aspirin undergoes

moderate hydrolysis to salicylic acid in the liver and the gastrointestinal wall, with 50%–75% of an

administered dose reaching the systemic circulation as intact aspirin.

Effect of Food

Dipyridamole:

When Aspirin and Extended-Release Dipyridamole Capsules were taken with a high fat meal,

dipyridamole peak plasma levels (C

) and total absorption (AUC) were decreased at steady-state by

20-30% compared to fasting. Due to the similar degree of inhibition of adenosine uptake at these plasma

concentrations, this food effect is not considered clinically relevant.

Aspirin:

When Aspirin and Extended-Release Dipyridamole Capsules were taken with a high fat meal, there was

no difference for aspirin in AUC at steady-state, and the approximately 50% decrease in C

was not

considered clinically relevant based on a similar degree of cyclooxygenase inhibition comparing the

fed and fasted state.

Distribution

Dipyridamole:

Dipyridamole is highly lipophilic (log P=3.71, pH=7); however, it has been shown that the drug does

not cross the blood-brain barrier to any significant extent in animals. The steady-state volume of

distribution of dipyridamole is about 92 L. Approximately 99% of dipyridamole is bound to plasma

proteins, predominantly to alpha 1-acid glycoprotein and albumin.

Aspirin:

Aspirin is poorly bound to plasma proteins and its apparent volume of distribution is low (10 L). Its

metabolite, salicylic acid, is highly bound to plasma proteins, but its binding is concentration-dependent

(nonlinear). At low concentrations (<100 mcg/mL), approximately 90% of salicylic acid is bound to

albumin. Salicylic acid is widely distributed to all tissues and fluids in the body, including the central

nervous system, breast milk, and fetal tissues. Early signs of salicylate overdose (salicylism), including

tinnitus (ringing in the ears), occur at plasma concentrations approximating 200 mcg/mL [see Overdosage

( 10)] .

Metabolism and Elimination

Dipyridamole:

Dipyridamole is metabolized in the liver, primarily by conjugation with glucuronic acid, of which

monoglucuronide which has low pharmacodynamic activity is the primary metabolite. In plasma, about

80% of the total amount is present as parent compound and 20% as monoglucuronide. Most of the

glucuronide metabolite (about 95%) is excreted via bile into the feces, with some evidence of

enterohepatic circulation. Renal excretion of parent compound is negligible and urinary excretion of the

glucuronide metabolite is low (about 5%). With intravenous (i.v.) treatment of dipyridamole, a triphasic

profile is obtained: a rapid alpha phase, with a half-life of about 3.4 minutes, a beta phase, with a half-

life of about 39 minutes, (which, together with the alpha phase accounts for about 70% of the total area

under the curve, AUC) and a prolonged elimination phase λ

with a half-life of about 15.5 hours.

Because of the extended absorption phase of the dipyridamole component, only the terminal phase is

apparent from oral treatment with Aspirin and Extended-Release Dipyridamole Capsules which was

13.6 hours.

Aspirin:

Aspirin is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 20 minutes. Plasma levels

of aspirin are essentially undetectable 2-2.5 hours after dosing and peak salicylic acid concentrations

occur 1 hour (range: 0.5-2 hours) after administration of aspirin. Salicylic acid is primarily conjugated

in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor

metabolites. Salicylate metabolism is saturable and total body clearance decreases at higher serum

concentrations due to the limited ability of the liver to form both salicyluric acid and phenolic

glucuronide. Following toxic doses (10-20 g), the plasma half-life may be increased to over 20 hours.

The elimination of acetylsalicylic acid follows first-order kinetics with Aspirin and Extended-Release

Dipyridamole Capsules and has a half-life of 0.33 hours. The half-life of salicylic acid is 1.71 hours.

Both values correspond well with data from the literature at lower doses which state a resultant half-

life of approximately 2-3 hours. At higher doses, the elimination of salicylic acid follows zero-order

kinetics (i.e., the rate of elimination is constant in relation to plasma concentration), with an apparent

half-life of 6 hours or higher. Renal excretion of unchanged drug depends upon urinary pH. As urinary

pH rises above 6.5, the renal clearance of free salicylate increases from <5% to >80%. Alkalinization

of the urine is a key concept in the management of salicylate overdose [see Overdosage ( 10)] .

Following therapeutic doses, about 10% is excreted as salicylic acid and 75% as salicyluric acid, as

the phenolic and acyl glucuronides, in urine.

Specific Populations

Geriatric Patients:

Dipyridamole:

In ESPS2 [see Clinical Studies ( 14)] , plasma concentrations (determined as AUC) of dipyridamole in

healthy elderly subjects (>65 years) were about 40% higher than in subjects younger than 55 years

receiving treatment with Aspirin and Extended-Release Dipyridamole Capsules.

Hepatic Dysfunction:

No study has been conducted with Aspirin and Extended-Release Dipyridamole Capsules in patients

with hepatic dysfunction.

Dipyridamole:

In a study conducted with an intravenous formulation of dipyridamole, patients with mild to severe

hepatic insufficiency showed no change in plasma concentrations of dipyridamole but showed an

increase in the pharmacologically inactive monoglucuronide metabolite. Dipyridamole can be dosed

without restriction as long as there is no evidence of hepatic failure.

Aspirin:

Avoid aspirin in patients with severe hepatic insufficiency.

Renal Dysfunction:

Dipyridamole:

In ESPS2 patients [see Clinical Studies ( 14)] , with creatinine clearances ranging from about 15 mL/min

to >100 mL/min, no changes were observed in the pharmacokinetics of dipyridamole or its glucuronide

metabolite if data were corrected for differences in age.

Aspirin:

Avoid aspirin in patients with severe renal failure (glomerular filtration rate <10 mL/min).

Drug Interaction Studies

A dedicated drug interaction study was conducted in 60 healthy volunteers to evaluate the effects of

omeprazole 80 mg administered once daily on the pharmacokinetics (PK) of dipyridamole and the

pharmacodynamics (PD) of acetylsalicylic acid when co-administered with Aspirin and Extended-

Release Dipyridamole Capsules twice daily. Dipyridamole exposure (C

and AUC) at steady-state

were similar with or without omeprazole co-administration. The pharmacokinetics of acetylsalicylic

acid was not characterized. However, the antiplatelet activity as measured by arachidonic acid induced

platelet aggregation was similar between the treatment arms at steady-state.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In studies in which dipyridamole was administered in the feed to mice (up to 111 weeks in males and

females) and rats (up to 128 weeks in males and up to 142 weeks in females), there was no evidence of

drug-related carcinogenesis. The highest dose administered in these studies (75 mg/kg/day) was, on a

mg/m

basis, about equivalent to the maximum recommended daily human oral dose (MRHD) in mice

and about twice the MRHD in rats.

Combinations of dipyridamole and aspirin (1:5 ratio) tested negative in the Ames test, in vivo

chromosome aberration tests (in mice and hamsters), oral micronucleus tests (in mice and hamsters) and

oral dominant lethal test (in mice). Aspirin, alone, induced chromosome aberrations in cultured human

fibroblasts. Mutagenicity tests of dipyridamole alone with bacterial and mammalian cell systems were

negative.

Combinations of dipyridamole and aspirin have not been evaluated for effects on fertility and

reproductive performance. There was no evidence of impaired fertility when dipyridamole was

administered to male and female rats at oral doses up to 500 mg/kg/day (about 12 times the MRHD on a

mg/m

basis). A significant reduction in number of corpora lutea with consequent reduction in

implantations and live fetuses was, however, observed at 1250 mg/kg (more than 30 times the MRHD on

a mg/m

basis). Aspirin inhibits ovulation in rats.

14 CLINICAL STUDIES

ESPS2 (European Stroke Prevention Study-2) was a double-blind, placebo-controlled, 24-month study in

which 6602 patients over the age of 18 years had an ischemic stroke (76%) or transient ischemic attack

(TIA, 24%) within three months prior to entry. Patients were enrolled in 13 European countries between

February 1989 and May 1995 and were randomized to one of four treatment groups: Aspirin and

Extended-Release Dipyridamole Capsules 25 mg/200 mg; extended-release dipyridamole (ER-DP) 200

mg alone; aspirin (ASA) 25 mg alone; or placebo. The mean age in this population was 66.7 years with

58% of them being males. Patients received one capsule twice daily (morning and evening). Efficacy

assessments included analyses of stroke (fatal or nonfatal) and death (from all causes) as confirmed by a

blinded morbidity and mortality assessment group. There were no differences with regard to efficacy

based on age or gender; patients who were older had a trend towards more events.

Stroke Endpoint

Aspirin and Extended-Release Dipyridamole Capsules reduced the risk of stroke by 22.1% compared to

aspirin 50 mg/day alone (p = 0.008) and reduced the risk of stroke by 24.4% compared to extended-

release dipyridamole 400 mg/day alone (p = 0.002) (Table 3). Aspirin and Extended-Release

Dipyridamole Capsules reduced the risk of stroke by 36.8% compared to placebo (p <0.001).

Table 3 Summary of First Stroke (Fatal or Nonfatal): ESPS2: Intent-to-Treat Population

Total

Number

of

Patients

n

Number of

Patients

With

Stroke

Within 2

Years

n (%)

Kaplan-

Meier

Estimate

of Survival at

2 Years

(95% C.I.)

Gehan-

Wilcoxon

Test

P-value

Ris k

Reduction

at 2 Years

Odds

Ratio

(95%

C.I.)

Individual Treatment

Group

Aspirin and Extended-Release

Dipyridamole Capsules

1650

157 ( 9.5%)

89.9%

(88.4%,

91.4%)

-

-

-

ER-DP

1654

211 (12.8%)

86.7%

(85.0%,

88.4%)

-

-

-

1649

206 (12.5%)

87.1%

(85.4%,

88.7%)

-

-

-

Placebo

1649

250 (15.2%)

84.1%

(82.2%,

85.9%)

-

-

-

Pairwise Treatment Group Comparisons

0.010 <p value ≤0.050;

p value ≤0.010.

Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for

all treatment groups is BID.

Aspirin and Extended-Release

Dipyridamole Capsules vs.

ER-DP

-

-

-

0.002

24.4%

0.72

(0.58,

0.90)

Aspirin and Extended-Release

Dipyridamole Capsules vs.

-

-

-

0.008

22.1%

0.74

(0.59,

0.92)

Aspirin and Extended-Release

Dipyridamole Capsules vs.

Placebo

-

-

-

<0.001

36.8%

0.59

(0.48,

0.73)

ER-DP vs. Placebo

-

-

-

0.036

16.5%

0.82

(0.67,

1.00)

ASA vs. Placebo

-

-

-

0.009

18.9%

0.80

(0.66,

0.97)

Figure 1 ESPS2: Cumulative Stroke Rate (Fatal or Nonfatal)

Over 24 months of Follow-Up

Combined Stroke or Death Endpoint

In ESPS2, Aspirin and Extended-Release Dipyridamole Capsules reduced the risk of stroke or death by

24.2% compared to placebo.

Aspirin and Extended-Release Dipyridamole Capsules reduced the risk of stroke or death by 12.1%

compared to aspirin alone and by 10.3% compared to extended-release dipyridamole alone. These

results were not statistically significant.

Death Endpoint

The incidence rate of all-cause mortality was 11.3% for Aspirin and Extended-Release Dipyridamole

Capsules, 11.0% for aspirin alone, 11.4% for extended-release dipyridamole alone and 12.3% for

placebo alone. The differences between the Aspirin and Extended-Release Dipyridamole Capsules,

aspirin alone and extended-release dipyridamole alone treatment groups were not statistically

significant. These incidence rates for Aspirin and Extended-Release Dipyridamole Capsules and aspirin

alone are consistent with previous aspirin studies in stroke and TIA patients.

16 HOW SUPPLIED/STORAGE AND HANDLING

Aspirin and Extended-Release Dipyridamole Capsules are available as a No. 00 capsule with Pink

Opaque cap and Yellow Opaque body imprinted in black with “ Lannett” and “330”, and filled with

pellets and powder blend.

Aspirin and Extended-Release Dipyridamole Capsules are supplied in unit-of-use bottles of 60

capsules (NDC 51407-271-60).

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room

Temperature]. Protect from excessive moisture.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling ( Patient Information).

Risk of Bleeding

Inform patients that as with other antiplatelet agents, there is a general risk of bleeding including

intracranial and gastrointestinal bleeding. Inform patients about the signs and symptoms of bleeding,

including occult bleeding. Tell patients to notify their physician if they are prescribed any drug which

may increase risk of bleeding.

Counsel patients who consume three or more alcoholic drinks daily about the bleeding risks involved

with chronic, heavy alcohol use while taking aspirin.

Pregnancy

Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant

during treatment with Aspirin and Extended-Release Dipyridamole Capsules [see Use in Specific

Populations ( 8.1)] .

Headaches

Some patients may experience headaches upon treatment initiation; these are usually transient. In case of

intolerable headaches, tell patients to contact their physician.

Stress Test

Instruct patients who are scheduled to undergo a pharmacologic stress test to tell their healthcare

provider that they are taking Aspirin and Extended-Release Dipyridamole Capsules.

Dosage and Administration

Tell patients that Aspirin and Extended-Release Dipyridamole Capsules should be swallowed whole,

and not chewed or crushed. If you miss a dose, continue with your next dose on your regular schedule.

Do not take a double dose.

Storage

Inform patients to protect Aspirin and Extended-Release Dipyridamole Capsules from moisture.

Distributed by:

Lannett Company, Inc.

Philadelphia, PA 19136

CIA76452B

Rev. 01/2020

Marketed/Packaged by:

GSMS, Inc.

Camarillo, CA USA 93012

Patient Information

Aspirin (as-per-in) and Extended-Release Dipyridamole (dahy-pir-i-duh-mohl) Capsules

Read this Patient Information before you start taking Aspirin and Extended-Release Dipyridamole

Capsules and each time you get a refill. There may be new information. This information does not take

the place of talking to your healthcare provider about your medical condition or your treatment.

What is Aspirin and Extended-Release Dipyridamole Capsules?

Aspirin and Extended-Release Dipyridamole Capsules are a prescription medicine that contains aspirin

and a medicine that is slowly released in your body, called dipyridamole. Aspirin and Extended-Release

Dipyridamole Capsules are used to lower the risk of stroke in people who have had a "mini-stroke"

(transient ischemic attack or TIA) or stroke due to a blood clot.

It is not known if Aspirin and Extended-Release Dipyridamole Capsules are safe and effective in

children. See "Who should not take Aspirin and Extended-Release Dipyridamole Capsules?"

Who should not take Aspirin and Extended-Release Dipyridamole Capsules?

Do not take Aspirin and Extended-Release Dipyridamole Capsules if you:

are allergic to any of the ingredients in Aspirin and Extended-Release Dipyridamole Capsules. See

the end of this leaflet for a list of ingredients in Aspirin and Extended-Release Dipyridamole

Capsules.

are allergic to non-steroidal anti-inflammatory drugs (NSAIDs)

have asthma in combination with runny nose and nasal polyps

Do not give Aspirin and Extended-Release Dipyridamole Capsules to a child or teenager with a

viral illness. Reye syndrome, a life-threatening condition, can happen when aspirin (an ingredient

in Aspirin and Extended-Release Dipyridamole Capsules) is used in children and teenagers who

have certain viral illnesses.

What should I tell my doctor before using Aspirin and Extended-Release Dipyridamole

Caps ules ?

Before taking Aspirin and Extended-Release Dipyridamole Capsules, tell your healthcare

provider if you:

have stomach ulcers

have a history of bleeding problems

have heart problems

have kidney or liver problems

have low blood pressure

have myasthenia gravis

have any other medical conditions

are pregnant or plan to become pregnant. You should not take Aspirin and Extended-Release

Dipyridamole Capsules during pregnancy without first talking to your healthcare provider. Tell

your healthcare provider right away if you become pregnant while taking Aspirin and Extended-

Release Dipyridamole Capsules.

are breast-feeding or plan to breast-feed. Aspirin and Extended-Release Dipyridamole Capsules can

pass into your milk. Talk to your healthcare provider about the best way to feed your baby if you

take Aspirin and Extended-Release Dipyridamole Capsules.

Tell your doctor you are taking Aspirin and Extended-Release Dipyridamole Capsules if you are

scheduled to have a stress test for your heart.

Tell your doctor about all the medicines you take, including prescription and non-prescription

medicines, vitamins and herbal supplements. Aspirin and Extended-Release Dipyridamole Capsules and

other medicines may affect each other causing side effects. Aspirin and Extended-Release

Dipyridamole Capsules may affect the way other medicines work, and other medicines may affect how

Aspirin and Extended-Release Dipyridamole Capsules works.

Especially tell your healthcare provider if you take:

a medicine for high blood pressure, irregular heart beat, or heart failure

acetazolamide [Diamox

]

any blood thinner medicines

warfarin sodium [Coumadin

, Jantoven

]

a heparin medicine

anagrelide [Agrylin

]

a seizure medicine

a medicine for Alzheimer’s disease

a water pill

methotrexate sodium [Trexall

]

aspirin or a non-steroidal anti-inflammatory drug (NSAIDs). You should not take NSAIDs

during treatment with Aspirin and Extended-Release Dipyridamole Capsules. Using these

medicines with Aspirin and Extended-Release Dipyridamole Capsules can increase your risk of

bleeding.

a medicine for diabetes

probenecid [Probalan

, Col-Probenecid

]

Ask your healthcare provider or pharmacist if you are not sure if your medicine is one that is listed

above.

Know the medicines you take. Keep a list of them and show your healthcare provider and pharmacist

when you get a new medicine.

How should I take Aspirin and Extended-Release Dipyridamole Capsules?

Take Aspirin and Extended-Release Dipyridamole Capsules exactly as prescribed. Your healthcare

provider will tell you how many Aspirin and Extended-Release Dipyridamole Capsules to take and

when to take them.

Headaches are not uncommon when you first start taking Aspirin and Extended-Release

Dipyridamole Capsules, but often lessen as treatment continues. Tell your healthcare provider if

you have a severe headache. Your healthcare provider may change the instructions for taking

Aspirin and Extended-Release Dipyridamole Capsules.

Swallow Aspirin and Extended-Release Dipyridamole Capsules whole. Do not crush or chew the

capsules.

You can take Aspirin and Extended-Release Dipyridamole Capsules with or without food.

If you miss a dose, take your next dose at the usual time. Do not take two doses at one time.

If you take more Aspirin and Extended-Release Dipyridamole Capsules (overdose) than prescribed,

call your healthcare provider or Poison Control Center, or get emergency help right away.

Symptoms of an overdose of Aspirin and Extended-Release Dipyridamole Capsules include:

a warm feeling or flushing

sweating

restlessness

weakness or dizziness

a fast heart rate

ringing in the ears

What should I avoid while using Aspirin and Extended-Release Dipyridamole Capsules?

heavy alcohol use. People who drink three or more alcoholic drinks every day have a higher risk

®

®

®

®

®

®

®

of bleeding during treatment with Aspirin and Extended-Release Dipyridamole Capsules, because it

contains aspirin.

What are the possible side effects of Aspirin and Extended-Release Dipyridamole Capsules?

Aspirin and Extended-Release Dipyridamole Capsules may cause serious side effects, including:

increased risk of bleeding. You may bleed more easily during Aspirin and Extended-Release

Dipyridamole Capsules treatment, and it may take longer than usual for bleeding to stop. This can

include:

bleeding into your brain (intracranial hemorrhage). This can be a medical emergency. Get

medical help right away if you have any of these symptoms while taking Aspirin and Extended-

Release Dipyridamole Capsules:

severe headache with drowsiness

confusion or memory change

pass out (become unconscious)

bleeding in your stomach or intestine.

stomach pain

heartburn or nausea

vomiting blood or vomit looks like "coffee grounds"

red or bloody stools

black stools that look like tar

new or worsening chest pain in some people with heart disease. Tell your healthcare provider

if you have new chest pain or have any change in your chest pain during treatment with Aspirin and

Extended-Release Dipyridamole Capsules.

liver problems, including increased liver function tests and liver failure. Tell your healthcare

provider if you have any of these symptoms of a liver problem while taking Aspirin and Extended-

Release Dipyridamole Capsules:

loss of appetite

pale colored stool

stomach area (abdomen) pain

yellowing of your skin or whites of your eyes

dark urine

itching

Call your healthcare provider right away if you have any of the symptoms listed above.

The most common side effects of Aspirin and Extended-Release Dipyridamole Capsules include:

headache

upset stomach

diarrhea

These are not all the possible side effects of Aspirin and Extended-Release Dipyridamole Capsules.

Tell your healthcare provider or pharmacist if you have any side effect that bothers you or that does not

go away.

Call your healthcare provider for medical advice about side effects. You may report side effects to

FDA at 1-800-FDA-1088.

How should I store Aspirin and Extended-Release Dipyridamole Capsules?

Store Aspirin and Extended-Release Dipyridamole Capsules at room temperature 68°F to 77°F

(20°C to 25°C).

Keep Aspirin and Extended-Release Dipyridamole Capsules dry.

Keep Aspirin and Extended-Release Dipyridamole Capsules and all medicines out of the reach of

children.

General information about Aspirin and Extended-Release Dipyridamole Capsules

Medicines are sometimes prescribed for purposes other than those listed in the Patient Information. Do

not use Aspirin and Extended-Release Dipyridamole Capsules for a condition for which it was not

prescribed. Do not give Aspirin and Extended-Release Dipyridamole Capsules to other people, even if

they have the same symptoms that you have. It may harm them.

This Patient Information summarizes the most important information about Aspirin and Extended-Release

Dipyridamole Capsules. If you would like more information, talk with your healthcare provider. You

can ask your pharmacist or healthcare provider for information about Aspirin and Extended-Release

Dipyridamole Capsules that is written for health professionals.

For more information, call Lannett Company, Inc. at 1-844-834-0530.

What are the ingredients in Aspirin and Extended-Release Dipyridamole Capsules?

Active Ingredients: dipyridamole in an extended-release form and aspirin

Inactive Ingredients: hydrogenated castor oil, hypromellose 2910, hypromellose phthalate,

methacrylic acid copolymer, microcrystalline cellulose, povidone, simethicone emulsion, starch, talc,

tartaric acid and triacetin. The imprinting ink also contains ammonium hydroxide, n-butyl alcohol, black

iron oxide, isopropyl alcohol, propylene glycol and shellac glaze. Each capsule shell contains gelatin,

red iron oxide and yellow iron oxide and titanium dioxide.

Distributed by:

Lannett Company, Inc.

Philadelphia, PA 19136

CIB71937B

Rev. 01/2020

Marketed/Packaged by:

GSMS, Inc.

Camarillo, CA USA 93012

Aspirin and Dipyridamole 25mg/200mg ER Capsules 60

NDC 51407-271-60

ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE

aspirin and extended-release dipyridamole capsule, extended release

Product Information

Product T ype

HUMAN PRESCRIPTION DRUG

Ite m Code (Source )

NDC:5140 7-271(NDC:6 2175-330 )

Route of Administration

ORAL

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

Stre ng th

ASPIRIN (UNII: R16 CO5Y76 E) (ASPIRIN - UNII:R16 CO5Y76 E)

ASPIRIN

25 mg

DIPYRIDAMO LE (UNII: 6 4ALC7F9 0 C) (DIPYRIDAMOLE - UNII:6 4ALC7F9 0 C)

DIPYRIDAMOLE

20 0 mg

Inactive Ingredients

Ingredient Name

Stre ng th

AMMO NIA (UNII: 5138 Q19 F1X)

BUTYL ALCO HO L (UNII: 8 PJ6 1P6 TS3)

DIMETHICO NE (UNII: 9 2RU3N3Y1O)

FERRIC O XIDE RED (UNII: 1K0 9 F3G6 75)

Golden State Medical Supply

FERRIC O XIDE YELLO W (UNII: EX438 O2MRT)

FERRO SO FERRIC O XIDE (UNII: XM0 M8 7F357)

GELATIN (UNII: 2G8 6 QN327L)

HYDRO GENATED CASTO R O IL (UNII: ZF9 4AP8 MEY)

HYPRO MELLO SE 2 9 10 ( 15 MPA.S) (UNII: 36 SFW2JZ0 W)

HYPRO MELLO SE PHTHALATE ( 3 1% PHTHALATE, 4 0 CST) (UNII: G4U0 24CQK6 )

ISO PRO PYL ALCO HO L (UNII: ND2M416 30 2)

METHACRYLIC ACID - METHYL METHACRYLATE CO PO LYMER ( 1:2 ) (UNII: 5KY6 8 S2577)

MICRO CRYSTALLINE CELLULO SE (UNII: OP1R32D6 1U)

PO VIDO NE (UNII: FZ9 8 9 GH9 4E)

PRO PYLENE GLYCO L (UNII: 6 DC9 Q16 7V3)

SHELLAC (UNII: 46 N10 7B71O)

STARCH, CO RN (UNII: O8 232NY3SJ)

TALC (UNII: 7SEV7J4R1U)

TARTARIC ACID (UNII: W48 8 8 I119 H)

TITANIUM DIO XIDE (UNII: 15FIX9 V2JP)

TRIACETIN (UNII: XHX3C3X6 73)

Product Characteristics

Color

pink (o paque) , yello w (o paque)

S core

no sco re

S hap e

CAPSULE (capsule)

S iz e

24mm

Flavor

Imprint Code

La nne tt;330

Contains

Packag ing

#

Item Code

Package Description

Marketing Start Date

Marketing End Date

1

NDC:5140 7-271-6 0

6 0 in 1 BOTTLE; Type 0 : No t a Co mbinatio n Pro duct

0 8 /22/20 19

Marketing Information

Marke ting Cate gory

Application Numbe r or Monograph Citation

Marke ting Start Date

Marke ting End Date

ANDA

ANDA20 4552

0 3/20 /20 19

Labeler -

Golden State Medical Supply (603184490)

Establishment

Name

Ad d re s s

ID/FEI

Busine ss Ope rations

Go lden State Medical Supply

6 0 318 449 0

relabel(5140 7-271) , repack(5140 7-271)

Revised: 2/2020

Similar products

Search alerts related to this product

View documents history

Share this information